elevated heart rate tirzepatide Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice High resting heart rate on

placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes

Even modest reductions of 3-5% can decrease steatosis

The Future of Personalized Medicine As the healthcare industry shifts toward precision medicine, services like Brello are leading the way

Plus, our L-Carnitine drink is 100% vegan and available in a delicious taste: Crazy Apple